Akebia Therapeutics, Inc. (AKBA)
$
3.14
+0.01 (0.32%)
Key metrics
Financial statements
Free cash flow per share
-0.0096
Market cap
832.6 Million
Price to sales ratio
4.0865
Debt to equity
1.8260
Current ratio
1.9766
Income quality
0.0659
Average inventory
18.2 Million
ROE
3.1876
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney diseases. The company's lead investigational product candidate, vadadustat, is an oral therapy currently in Phase III trials aimed at treating anemia caused by chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis dependent adult patients. Additionally, Akebia provides Auryxia, a ferric citrate medication that helps control serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease (DD-CKD) and addresses iron deficiency anemia in those not on dialysis. The weighted average number of diluted shares outstanding is 210,946,658.00 reflecting potential dilution effects, while the company’s stock is identified with the symbol 'AKBA' in the market. Akebia has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat across a broad range of regions, including the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries. Furthermore, it has partnered with Mitsubishi Tanabe Pharma Corporation for similar efforts in Japan and other Asian markets. Akebia also maintains a research and license agreement with Janssen Pharmaceutica NV to advance hypoxia-inducible factor prolyl hydroxylase targeted compounds on a global scale. The company earned an interest income of $0.00 showcasing its financial investments, and incurred an income tax expense of $0.00 indicating its tax obligations. The net income ratio is -0.43 reflecting the company's profitability margin. The company's stock is affordable at $3.97 making it an appealing option for budget-conscious investors. Additionally, the stock has a high average trading volume of 4,572,134.00 indicating strong liquidity. With a market capitalization of $832,555,297.00 the company is classified as a small-cap player in the industry. Akebia Therapeutics is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.
Is Akebia Therapeutics, Inc. (AKBA) a good investment?
Investing in Akebia Therapeutics, Inc. (AKBA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Akebia Therapeutics, Inc. (AKBA)'s stock forecast?
Analysts predict Akebia Therapeutics, Inc. stock to fluctuate between $1.24 (low) and $4.08 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Akebia Therapeutics, Inc.'s market capitalization?
As of 2025-08-29, Akebia Therapeutics, Inc.'s market cap is $832,555,297, based on 265,144,999 outstanding shares.
How does Akebia Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Akebia Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Akebia Therapeutics, Inc. (AKBA) stock?
To buy Akebia Therapeutics, Inc. (AKBA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AKBA. Place an order (Market, Limit, etc.).
What is the best time to invest in Akebia Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Akebia Therapeutics, Inc. perform in the last earnings report?
Revenue: $160,180,000 | EPS: -$0.33 | Growth: 17.86%.
Where can I find Akebia Therapeutics, Inc.'s investor relations reports?
Visit https://www.akebia.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Akebia Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Akebia Therapeutics, Inc. stock?
All-time high: $4.08 (2025-07-11) | All-time low: $0.24 (2022-10-24).
What are the key trends affecting Akebia Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
I'm bullish on Akebia at $3.13, viewing the 21% post-earnings dip as a buying opportunity ahead of major revenue catalysts. Vafseo's rapid adoption and DaVita's pilot could double Akebia's addressable dialysis market, driving significant near-term revenue growth and profitability. Despite a mixed EPS, strong topline growth and stable Auryxia sales highlight Akebia's transition from speculative biotech to commercial-stage company.
seekingalpha.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director Mercedes Carrasco - Senior Director of Investor & Corporate Communications Nicholas Grund - Senior VP & Chief Commercial Officer Conference Call Participants Julian Reed Harrison - BTIG, LLC, Research Division Mazahir Lukman Alimohamed - Leerink Partners LLC, Research Division Roger Song - Jefferies LLC, Research Division Operator Good day and thank you for standing by.
zacks.com
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
zacks.com
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
zacks.com
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
globenewswire.com
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, and Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C.
seekingalpha.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call.
zacks.com
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
zacks.com
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
See all news
